Lung Cancer Clinical Trials Overview

SCCA Clinical Studies: Lung Cancer

Alisertib (MLN8237) in Combination With Paclitaxel for Small Cell Lung Cancer (UW14002)
A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC).
Status Conditions Phase Study ID
Pending Small Cell Lung Cancer Phase II UW14002

This is a two-arm, randomized, double-blind, placebo-controlled, multicenter, phase 2 study designed to evaluate the efficacy and safety of alisertib, an Aurora A kinase inhibitor, in combination with paclitaxel compared with placebo + paclitaxel in patients with SCLC who have relapsed or did not respond to first line standard therapy.

Christina S. Baik, MD
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)

Each patient must meet all the following inclusion criteria to be enrolled in the study:

  1. Male or female patients ≥ 18 years old
  2. Have a pathologically (histology or cytology) confirmed diagnosis of SCLC
  3. Have received and progressed after a platinum-based standard chemotherapy regimen for first line treatment of SCLC, either limited stage (LS) or extensive stage (ES).
  4. Have measurable disease within ≤ 2 weeks before randomization. Clear radiographic evidence of disease progression after initial therapy should have been documented.
  5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 (PS 0-1).
  6. Patients with treated brain metastases (surgery, whole or stereotactic brain radiation) are allowed provided the lesions have been stable for at least 2 weeks and the patient is off steroids or is on a stable dose of steroids. Patients should be without neurologic dysfunction that would confound the evaluation of neurological and/or other AEs.
Exclusions (conditions that would prevent participation in this study)

Patients meeting any of the following exclusion criteria are not to be randomized to treatment:

  1. Any prior therapy for second-line treatment of SCLC.
  2. Patients who relapsed ≥ 180 days after their response to first-line treatment.
  3. Prior treatment with an Aurora A specific-targeted or pan-Aurora-targeted agent, including alisertib, or any other investigational agent.
  4. Prior treatment with paclitaxel or any other taxane agent.
  5. Known hypersensitivity to Cremophor® EL, paclitaxel, or its components.
  6. Any comorbid condition or unresolved toxicity that would preclude administration of alisertib or weekly paclitaxel.
  7. Prior history of ≥ Grade 2 neurotoxicity that is not resolved to ≤ Grade 1
  8. Patients with symptomatic and/or progressive brain metastases or with carcinomatous meningitis.
  9. Treatment with clinically significant enzyme inducers within 14 days prior to the first dose of alisertib and during study conduct. Major prohibited enzyme inducers include: phenytoin, carbamazepine, phenobarbital, rifampin, rifabutin, rifapentine, and St. John's wort.
  10. Inability to swallow alisertib or other orally administered medications.
  11. Requirement for administration of proton pump inhibitor (PPI), H2 antagonist, or pancreatic enzymes.
  12. Diagnosed with or treated for another malignancy within 2 years before the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease.
  13. Other severe acute or chronic medical or psychiatric condition(s) per protocol.
  14. History of myocardial infarction, unstable symptomatic ischemic heart disease, uncontrolled hypertension despite appropriate medical therapy, any ongoing cardiac arrhythmias of Grade > 2, thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or any other cardiac condition (eg, pericardial effusion or restrictive cardiomyopathy) within 6 months before receiving the first dose of study drug.
  15. Known history of human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C.
  16. Surgery within 3 weeks (or 2 weeks for a minor surgery) before study enrollment and not fully recovered to baseline or to a stable clinical status.
  17. Patients who are pregnant, lactating, or do not agree to use effective methods of contraception during the study treatment period through 6 months after the last dose of study drug per protocol.
Last Updated
July 18, 2014
See this trial at
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.